Why the study?
Does sotagliflozin reduce cardiovascular death and heart failure events in patients with diabetes and recent worsening heart failure?
Does sotagliflozin reduce cardiovascular death and heart failure events in patients with diabetes and recent worsening heart failure?
In patients with diabetes and recent worsening heart failure, sotagliflozin initiated around the time of discharge significantly reduces cardiovascular deaths and heart failure events.
Answers are grounded in this paper and cite their sources.
Supports initiation near discharge in diabetic patients with recent worsening HF; extends SGLT inhibitor benefits to the post-acute phase.
In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: